Nisa Investment Advisors
ELVN icon

Nisa Investment Advisors’s Enliven Therapeutics ELVN Stock Holding History

Nisa Investment Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Buy
1,209
+165
+16% +$7K ﹤0.01% 1772
2026
Q1 		$40.9K Buy
1,044
+455
+77% +$12.6K ﹤0.01% 1753
2025
Q4 		$9.07K Sell
589
-27
-4% -$538 ﹤0.01% 2267
2025
Q3 		$12.6K Sell
616
-89
-13% -$1.79K ﹤0.01% 2194
2025
Q2 		$14.1K Buy
705
+23
+3% +$435 ﹤0.01% 2100
2025
Q1 		$13.4K Sell
682
-11
-2% -$237 ﹤0.01% 2020
2024
Q4 		$15.6K Buy
693
+31
+5% +$804 ﹤0.01% 2016
2024
Q3 		$16.9K Buy
662
+607
+1,104% +$14.1K ﹤0.01% 1962
2024
Q2 		$1.28K Buy
55
+40
+267% +$842 ﹤0.01% 2463
2024
Q1 		$264 Buy
15
+6
+67% +$92 ﹤0.01% 2604
2023
Q4 		$125 Hold
9
– – ﹤0.01% 2602
2023
Q3 		$123 Sell
9
-7
-44% -$118 ﹤0.01% 2715
2023
Q2 		$327 Buy
+16
New +$323 ﹤0.01% 2644

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Nisa Investment Advisors's ELVN Position: Q2 2026 in Review

Nisa Investment Advisors increased its Enliven Therapeutics (ELVN) stake by 16% in Q2 2026, buying an estimated $7K and bringing the position to 1,209 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1772.

Nisa Investment Advisors first reported a position in ELVN in Q2 2023 and has held it in 13 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Nisa Investment Advisors held 1,209 shares of Enliven Therapeutics worth $61.4K as of Q2 2026.
  • Nisa Investment Advisors bought 165 Enliven Therapeutics shares in Q2 2026, an estimated $7K.
  • Enliven Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #1772 holding.
  • Nisa Investment Advisors first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.